3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
lanreotide
5
Octreotide
5
Everolimus
4
Dexmedetomidine
3
Cabergoline
3
pasireotide
2
Phenoxybenzamine
2
Carboplatin
2
trametinib
1
testosterone enanthate
1
surufatinib
1
selpercatinib
1
pralsetinib
1
pegvisomant
1
lutetium Lu 177 dotatate
1
lenvatinib
1
larotrectinib
1
gadoteridol
1
gadoterate meglumine
1
gadolinium ethoxybenzyl DTPA
1
gadodiamide
1
gadobutrol
1
gadobenic acid
1
entrectinib
1
dabrafenib
1
candesartan
1
arginyllysine
1
anlotinib
1
Vitamin D
1
Trimethoprim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Neuropsychological Tests
×
Endocrine
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled